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Abstract: Protoporphyrin IX (PPIX) is known to 
accumulate within human brain tumors following 
administration of 5-aminolevulinic acid (5-ALA). It then 
emits red fluorescence when exposed to ultraviolet light. On 
this basis, 5-ALA is often utilized intraoperatively to assist 
with the surgical resection of malignant gliomas. However, 
there is little knowledge of metabolic intermediates generated 
during 5-ALA conversion to PPIX. We therefore conducted 
an investigation of both serum and urinary intermediates in 
patients with brain tumors (n=40) and in healthy volunteers 
(n=8). Study subjects were each given a 1.0 gm oral dose of 5-
ALA, undergoing blood and urinary porphyrin determinations 
prior to and four hours after dosing. While baseline porphyrin 
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levels did not differ significantly between groups, urinary 
levels of coproporphyrins (I and III), and serum levels of 
uroporphyrins (I and III) at four hours were significantly 
higher in patients with brain tumors than in control subjects. 
The higher porphyrin levels corresponded with the strongest 
intraoperative PPIX fluorescence. Observed porphyrin 
elevations were subsequently attributed to efflux of 
metabolites after 5-ALA uptake by tumor cells. A rise in 
urinary coproporphyrin following 5-ALA challenge may thus 
have a role as a nonspecific tumor marker. 
Introduction:  
5-aminolevulinic acid (5-ALA) is a substrate of heme, synthesized from 
succinyl coenzyme A and glycine. It contributes to a chain of porphyrin 
intermediates (porphobilinogen, uroporphyrinogen and coproporphyrinogen) 
leading to mitochondrial generation of protoporphyrin IX (PPIX). The latter is 
then enzymatically converted to heme via ferrochelatase. These reactions 
proceed briskly in the liver and in erythrocyte precursors of even healthy 
individuals but are augmented in rapidly proliferating cells. With 5-ALA dosing, 
metabolism typically halts at porphobilinogen (PBG) due to rate-limiting PBG 
deaminase activity. However, the rate-limiting step in more active tumor cells 
shifts to ferrochelatase, so that PPIX accumulates instead; and it is this 
accumulation of PPIX which responds to ultraviolet light, emitting a red 
fluorescence. 
Intraoperative fluorescence, induced by 5-ALA, enables better visualization 
of brain tumors, facilitating surgical resection. Unfortunately, there are no 
reports investigating the fate of porphyrin intermediates in the blood and urine 
of such patients when this therapeutic adjunct is used. For our study, we 
examined urinary and serum porphyrin levels in patients with brain tumors after 
5-ALA administration, comparing parameters with healthy, similarly treated 
adult volunteers. 
 
Experimentals and Methods: 
Forty patients with brain tumors and eight healthy adult volunteers 
participated in this study. Patients with tumors were given 1.0 gm of 5-ALA 
orally, two hours before anesthesia, and intraoperative fluorescence was 
performed. Blood and urine samples were collected prior to and four hours after 
5-ALA dosing. The healthy volunteers were given the same 1.0 gm oral dose of 
5-ALA. Blood samples were obtained before dosing, then at two, four, and six 
hours afterward. Urine samples were taken prior to and four hours after dosing. 
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For all subjects, levels of 5-ALA, coproporphyrins (I and III), and 
uroporphyrins (I and III) were measured. 
Intraoperative fluorescence of brain tumors was achieved with a 
semiconductor laser device (VLD-V1 version 2 M & M Co., Ltd., Tokyo, 
Japan). The tumors were exposed to light of near-laser quality, with a peak 
wavelength of 405 nm and light output of 120 mW through optical fiber. The 
spectra of tumor emissions were analyzed by personal computer (Figure 1). The 
aim was to identify PPIX fluorescence (at peak wavelength of 636 nm) and to 
quantitate its relative intensity (>3000, strong [Fig 2]; <3000, weak [Fig 3]). 
These two parameters corresponded with direct observations�that is, a tumor 
with strong quantitative fluorescence also displayed strong visible red 
fluorescence. All urinary concentrations were adjusted for creatinine values. 
The results were analysed statistically using the Dunnet method. 
 
Results  
Twenty tumors were strongly fluorescent (16 malignant gliomas, one 
AT/RT, two meningiomas, one hemangioblastoma) and another 10 fluoresced 
weakly (three benign gliomas, one schwannoma, three metastatic brain tumors, 
three malignant lymphomas). At baseline and after 5-ALA administration, 
serum and urinary levels of 5-ALA, serum coproporphyrins (I and III), and 
urinary uroporphyrins (I and III) did not differ significantly between groups (ie, 
by degree of tumor fluorescence). On the other hand, there were significant 
differences after 5-ALA dosing between patients with strongly fluorescent 
tumors and healthy volunteers in terms of serum uroporphyrin I (Fig 4) and 
uroporphyrin III (Fig 5), and urinary coproporphyrin I (Fig 6) and 
coproporphyrin III (Fig 7) (p<0.005). After the 5-ALA administration, serum 
uroporphyrins (I and III) were also significantly lower in patients with weakly 
vs strongly fluorescent tumors (p<0.005), but there were no significant 
differences among volunteers. Furthermore, urinary coproporphyrins (I and III) 
were significantly higher in patients with weakly fluorescent tumors, compared 
with volunteers (p<0.005), but there was no significant difference compared 
with strongly fluorescent tumors. 
 
Discussion  
The clinical impact of porphyrins is underscored by disorders of synthesis. 
In these conditions, or so-called porphyrias, production of porphyrins and/or 
porphyrin precursors increase. Therefore, blood and urinary porphyrins of a 
healthy volunteer given 5-ALA (as a substrate of heme) would expectedly 
increase, as they did in our study. The reason may be that an excess of metabolic 
intermediates (ie, pophyrins) ultimately escapes into general circulation. 
In tumor-bearing mice, blood levels of porphyrins reportedly increase. 
However, the blood and urinary levels of porphyrins of humans with disease, 
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following administration of 5-ALA, have not been similarly documented. In this 
study, serum uroporphyrins (I and III) and urinary coproporphyrins (I and III) 
after 5-ALA administration were found to significantly increase in patients with 
brain tumors, relative to volunteers. Unlike healthy subjects, the ongoing 
synthesis of heme is accelerated in the hypermetabolic cells of tumors, so that 
PPIX accumulates in tumor cells when 5-ALA is given. Although PPIX 
accumulates, porphyrin intermediates, such as coproporphyrin and uroporphyrin, 
are still readily synthesized. The differences in intensity of tumor fluorescence 
likely reflect the extent of photoactive PPIX accumulation.  
Inclusive of volunteers, it was felt that variations in PPIX accumulation 
also accounted for differences in blood and urinary porphyrins after 5-ALA 
dosing. Then again, the fluorescent strength of tumors was not necessarily 
proportional to circulating porphyrins due to differing tumor volumes. 
Alternatively, other influences, such as ALA uptake by cells, mitochondrial 
properties, and molecules involved in PPIX metabolism (including 
porphobilinogen deaminase, ferrochelatase, iron content, and transferring 
receptor) must be considered. For example, ABCG2 and ABCB6 of the ATP-
binding cassette (ABC) transporter provide for trafficking of porphyrins. 
ABCB6 specifically facilitates transfer of coproporphyrinogen from the 
cytoplasm to mitochondria. Not only is ABCG2 overexpressed in malignant 
brain tumors, but there are genetic ABC polymorphisms genetic polymorphism 
that may add to the complexity of porphyrin metabolism. 
Nonetheless, the overriding factor for accumulation of PPIX is the 
hypermetabolism of tumor cells, which may serve as a nonspecific marker of 
tumor activity. In other words, a substantial rise in urinary coproporphyrins (I 
and III) after dosing with 5-ALA could be due to malignancy. 
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[Figure 1] Photo of intraoperative brain tumor fluorescence using 
semiconductor laser device (VLD-V1 version 2: M & M Co., Ltd., Tokyo, Japan). 
The tumor emits red fluorescence upon exposure to a laser light with peak 
wavelength of 405nm and a light output of 120mW through optical fiber. Tumor 
emissions were analyzed by personal computer via spectrometer through a 
second optical fiber in parallel. PPIX-specific fluorescence and relative 
intensity were measured.  
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[Figure 2] Intraoperative photo and fluorescent wave form of strongly 
fluorescent glioblastoma There is surface infiltration of brain by tumor; red 
fluorescence is in response to a laser beam of 405nm. The wave form, with peak 
at 636nm was confirmed as PPIX emission. Intensity of the peak was 5000. 
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 [Figure 3] Intraoperative view and fluorescent wave form of weakly fluorescent 
benign glioma. There is surface infiltration of brain by tumor (upper left); weak 
red fluorescence is in response to a laser beam of 405nm (upper right). The 
wave form, with low peak at 636nm, was confirmed as PPIX emission. Intensity 
of the peak was less than 1000 (lower). 
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[Figure 4] Comparison of the plasma uroporphyrin I levels four hours after the 
5-ALA administration. 
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Figure 5] Comparison of the plasma uroporphyrin III level four hours after the 
5-ALA administration. 
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[Figure6] Comparison of urine coproporphyrin I level four hours after the 
5-ALA administration. 
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[Figure 7] Comparison of urine coproporphyrin III level four hours after the 5-
ALA administration. 
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